TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05795621

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IBI311
Description: 10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IBI311
Description: 10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 does of placebo for phase II; 8 does of placebo for phase III.
Study: NCT06627712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT+PD-1 Inhibitor + Chemotherapy
Description: Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PD-1 Inhibitor + Chemotherapy
Description: Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study: NCT05405231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Line Facilitation (CLF)
Description: Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Implementation
Description: The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
Study: NCT06699134

Intervention type: DEVICE
Intervention: Total knee arthroplasty
Description: Primary total knee replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant

Intervention type: DEVICE
Intervention: Total Hip arthroplasty
Description: Primary total hip replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
Study: NCT06731803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan + 5FU/LV
Description: trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan + FLO
Description: trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles FLO: oxaliplatin 85 mg/m2 and leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
Study: NCT06733701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based intervention (VRReliever Software V0.3.4 fromXRHealth)
Description: The participant will be able to select between four VR environments: beach, lake, forest, or mountain scenery. Each provides an immersive audio and visual environment designed to reduce anxiety and promote relaxation. Each scene is rendered in a high-resolution and life-like fashion which participants can experience in a full 360 degrees. Participants will wear the headset for the duration of the egg retrieval procedure which is approximately 15-20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VR headset without any scenery
Description: VR headset without any scenery
Study: NCT06721351

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diabetic Retinopathy screening Point of Care Artificial Intelligence
Description: Random assignment of participants to intervention and control groups minimizes confounding variables. This ensures that any observed differences in outcomes are likely due to the intervention itself and not pre-existing differences between the groups. Participants of the DRES-POCAI study will be randomized into two groups: usual care (receive a retinal screening by an optometrist) or intervention group (receive a retinal screening using a special camera and EyeArt® system, an autonomous AI-based DR screening). The randomization will occur after consenting and completing the surveys, prior to conducting the DR screening process (for those randomized to the intervention group).
Study: NCT06741813

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ASCT
Description: The chemotherapy-based preconditioning regimen was BeEAM, which consisted of bendamustine (120-180 mg·m-2·day-1，days -8 to -7), etoposide (200 mg·m-2·day-1，days -6 to -3), cytarabine (400 mg·m-2·day-1，days -6 to -3), and melphalan (140 mg·m-2·day-1，days -2).
Study: NCT05301699

Intervention type: OTHER
Intervention: data analysis; validating the nomogram
Description: Not Applicable. Our study did not involve intervention

Intervention type: OTHER
Intervention: data analysis; validating the nomogram
Description: Not Applicable. Our study did not involve intervention
Study: NCT06550453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)
Description: Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity.
Study: NCT06302361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous anastomosis (LVA)
Description: Surgical procedure with supermicrosurgical anastomosis between distal lymph vessel and proximal venule.
Study: NCT05249920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol Concentrated Solution for injection
Description: Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edaravone Dexborneol placebo
Description: Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
Study: NCT05027282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.
Description: CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
Study: NCT06469853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-015 16 mg oral capsules
Description: MBF-015 oral capsules HDAC inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-015 16 mg oral capsules
Description: MBF-015 oral capsules HDAC inhibitor
Study: NCT05505890

Intervention type: OTHER
Intervention: suprainguinal fascia iliaca block
Description: Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
Study: NCT06579248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral Device
Description: Device that circulates cooled water through the oral cavity.
Study: NCT06013085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 6 weeks cognitive behavioral therapy
Study: NCT06088446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary anesthetic injections
Description: Supplementary anesthetic injections after failed primary nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary anesthetic injections
Description: Supplementary anesthetic injections after failed primary nerve block
Study: NCT06741813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Description: Chemotherapy-based preconditioning regimen consisted of cytarabine 4 g·m-2·day-1 (days -9), busulfan (3.2 mg·kg-1·day-1 administered intravenously on days -8 to -6) (day 0 being the first day of donor cell infusion), cyclophosphamide (1.8 g·m-2·day-1, days -5 to -4), and semustine (250 mg.m-2, day -3). For the patients older than 55 years old or with HCT-CI score of 3 or more, cyclophosphamide can be decreased to 1.0 g·m-2·day-1, days -5 to -4, and added fludarabine (30mg·m-2·day-1, days -6 to -2). Rabbit antithymocyte globulin (thymoglobulin, 1.5 to 2.5 mg/kg, days -5 to -2; Sanofi, France) was administered to the HID and URD groups or MSD HSCT recipients who older than 40 years old (1.5 mg/kg, days -4 to -2).~All MSD, HID, and URD HSCT recipinets received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate (MTX) for GVHD prophylaxis. CsA (2.5 mg/kg, q12h, intravenous \[i.v.\]) was used from day -9, of which the trough concentration was adjusted to 150-250 ng
Study: NCT06737913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAI Adebrelimab
Description: Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)
Study: NCT06329453

Intervention type: PROCEDURE
Intervention: Colon Tissue Biopsy
Description: Colonoscopy and colon tissue biopsy.

Intervention type: PROCEDURE
Intervention: Colon Tissue Biopsy
Description: Colonoscopy and colon tissue biopsy.

Intervention type: PROCEDURE
Intervention: Colon Tissue Biopsy
Description: Colonoscopy and colon tissue biopsy.
Study: NCT06737913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous infusion (IV) of Adebrelimab (ADE)
Description: intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous infusion (IV) of Bevacizumab (Bev.)
Description: intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous infusion (IV) of Bevacizumab (Bev.)
Description: intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC with FOLFOX regimen
Description: HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC with FOLFOX regimen
Description: HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and bevacizumab maintainance treatment
Description: The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and bevacizumab maintainance treatment
Description: The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity
Study: NCT06737887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoma simulation
Description: Patients who will undergo stoma surgery will have an intervention one day before the surgery. The adapter will be cut to an estimated stoma size, heated by rubbing with hands and adapted to the skin by applying stoma paste. The patient will be asked to place their hand on the adapter and apply pressure. Then, the stoma bag filled with tissues and water and the adapter will be combined. The patient will be informed that they should not hesitate to do any activity that they will spend 24 hours with the stoma bag. The patient will be provided with the opportunity to go to the toilet, eat, sleep and experience all their daily activities with the stoma. It allows patients to experience the stoma bag by putting it on 24 hours before the surgery. In this way, patients know that they will not encounter any surprises after the surgery.
Study: NCT06743373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis Discontinuation
Description: Cannabis-using participants will participate in an orientation session with a clinician and asked to abstain from cannabis use for four weeks, using established procedures for abstinence monitoring and reinforcement.
Study: NCT06742138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL2109
Description: QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
Study: NCT04835272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Decannulation Protocol With Suctioning
Description: In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
Study: NCT05332899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Type A H3N2 Challenge
Description: The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device or by natural exposure to infected participants. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
Study: NCT04129723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping biological therapy
Description: Stopping biological therapy The primary endpoint is clinical relapse at 12 months
Study: NCT06038448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter balloon size
Description: The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter balloon size
Description: The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
Study: NCT06742138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DARZALEX FASPRO®
Description: DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
Study: NCT04728828

Intervention type: BIOLOGICAL
Intervention: Serological COVID-19 vaccine immunogenicity
Description: Serological test
Study: NCT06741657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI
Description: Administered as specified in the treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBI
Description: Administered as specified in the treatment arm.
Study: NCT04926493

Intervention type: BIOLOGICAL
Intervention: microbiological characterization
Description: microbiological characterization of endotracheal tube biofilm
Study: NCT06355921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure.
Study: NCT05176574

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
Study: NCT06201299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Exercise Program
Description: The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chair-based Exercise Program
Description: The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
Study: NCT06165653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-Minute, Audio-Recorded Guided Mediation Practice
Description: Five different meditation practices will be provided, all of which have been validated in prior research.~* The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~* The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~* The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~* The Savoring practice consists of instruction in identifying and amplifying pleasant memories~* The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others
Study: NCT05403515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: foot massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage +Aromatherapy group
Description: foot massage and lavender oil inhalation
Study: NCT04201210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation
Description: Haploidentical 5+/10 HSCT from a relative, α/β T-depleted

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matched sibling donor transplantation
Description: 10/10 HSCT - matched family donor
Study: NCT04889911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care
Description: NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
Study: NCT06737783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self myofascial release with foam roller, T6- T7 Maitland mobilization + Conventional therapy
Description: Hamstring Self myofascial release with foam roller (Sitting with one leg extended, roll the foam roller along the hamstring while applying pressure to tender spots) 3 sets with 30 to 120 secs rolling duration per second for 5 mins T6-T7 grade 3 Maitland mobilization (Lying on the back, the therapist applies a sustained, posterior-to-anterior force on T6-T7 in prone position) 30 repetitions, with 1 min rest between 4 sets for 15 mins. Conventional therapy includes Hot pack/Cold pack + tens = 15 mins, Frequency 80 Hz, Pulse duration: 100 microseconds, Static quads (10 reps, 10 second hold, 2 sets), Active knee flexion and extension ROMs (10 reps, 5 secs hold, 2 sets), Long Axis Knee traction (5 reps, 30 secs hold, 10sec rest in b/w 2 sets), Kaltenborn Knee Glides Ant and Post direction ( 5 reps, 30 secs hold,10 sec rest interval in b/w 2 sets), Calf stretches (10 reps, 5 secs hold , 2 sets).
Study: NCT06741657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS
Description: Administered as specified in the treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS
Description: Administered as specified in the treatment arm.